MENU
  • About Us
    • Profile
  • Blog
    • Comment Policy
  • Series
    • Bispecific Antibody
    • ADC
    • CAR-T
    • KRAS Deep Dive
    • Oncology Approvals
  • Category
  • Contact Us
  • 日本語
  • English
Create the Most Advanced Therapeutics ~ Pharmas, Biotech Ventures, and Investors~
  • About Us
    • Profile
  • Blog
    • Comment Policy
  • Series
    • Bispecific Antibody
    • ADC
    • CAR-T
    • KRAS Deep Dive
    • Oncology Approvals
  • Category
  • Contact Us
  • 日本語
  • English
  • About Us
  • Blog
  • Series
  • Category
  • Contact Us
  • 日本語
  • English
Create the Most Advanced Therapeutics ~ Pharmas, Biotech Ventures, and Investors~
  • About Us
    • Profile
  • Blog
    • Comment Policy
  • Series
    • Bispecific Antibody
    • ADC
    • CAR-T
    • KRAS Deep Dive
    • Oncology Approvals
  • Category
  • Contact Us
  • 日本語
  • English
  1. Home
  2. vaccine

vaccine– tag –

  • Oncology Drug

    KRAS Cancer Vaccine Competitive Map: 4 Modalities Compared After Moderna/Merck V941’s Withdrawal

    Takeaway: the field is coalescing around shared neoantigens × off-the-shelf × adjuvant MRD. Elicio (ELI-002 7P) leads the pack; academic SLP + poly-ICLC programs and Gritstone’s SLATE-KRAS follow. With V941 halted, the landscape is clear...
    2025-10-09
  • Oncology FDA Approval

    CD388 (Cidara): What “One-Shot Seasonal Flu Protection” Could Mean for Vaccine Strategy

    A New Era in Flu Prevention? — CD388 Shows One-Shot Seasonal Protection Introduction Flu prevention has long relied on seasonal vaccines, but a new innovation may challenge that paradigm. CD388, a long-acting antiviral developed by Cidar...
    2025-07-08
  • Biotech Investment

    Biotech Investment News: GSK’s Major Deals from 2015 to 2025

    Strategic Review: Focused Expansion in Vaccines and Specialty Medicines Over the past decade, GSK has shifted from large-scale M&A to focused investments and strategic partnerships, particularly in vaccines, oncology, respiratory, an...
    2025-06-28
1
MorningMorning|管理人

創薬の最前線に20年以上。基礎研究から新薬開発、そして投資の側まで――投資家の視点も持ちながら、がん領域を軸に日米欧で歩いてきました。最先端のがん治療・創薬・AI創薬・バイオ投資を、正確に、面白く、毎日お届けします。

▶ もっと詳しく(プロフィール)

▶ X:@MorningGlorySci

コメント・ご質問、お待ちしています。

MorningMorning|Author

20+ years at the frontline of drug discovery — from basic research to development to the investor's side. Oncology-focused, across Japan, the US, and Europe. Cutting-edge cancer therapy, drug discovery, AI drug development, and biotech investment — accurate and engaging, every day.

▶ More (Profile)

▶ X: @MorningGlorySci

Comments & questions welcome.

  • Disclaimer
  • Privacy Policy
  • Sitemap
  • Contact Us
  • 日本語

© Create the Most Advanced Therapeutics ~ Pharmas, Biotech Ventures, and Investors~.

  • Menu
  • Disclaimer
  • Privacy Policy
  • Sitemap
  • Contact Us
  • 日本語